Despite promising pipeline launches through 2028, BSX faces significant headwinds: stock down 55.4% over 12 months vs. 29.7% industry decline, trades at premium valuation (2.85x forward P/S vs. 2.11 industry average), experiencing downward earnings estimate revisions, and expecting flat EP growth in H2 2026 due to intense competition. Zacks assigns a Strong Sell rating.
Despite positive analyst recommendations (ABR 1.53 - Strong Buy/Buy), the Zacks Rank assigns a #5 (Strong Sell) rating based on declining earnings estimate revisions (down 0.3% to $3.29). The article emphasizes that earnings estimate trends are more reliable predictors of near-term stock performance than analyst sentiment, indicating downward pressure on the stock.
Boston Scientific's WATCHMAN FLX and FLX Pro are highlighted as leading LAAC products. The company benefits from recent FDA approvals, strong market demand for stroke-prevention solutions, and the overall growth trajectory of the atrial fibrillation treatment devices market.
CEO's significant $10 million insider purchase of 208,000 shares signals strong confidence in future prospects. The purchase occurred despite recent -54% stock decline, suggesting management believes shares are undervalued. Company has strengthened product pipeline through acquisitions and is implementing $500 million operational cost cuts, indicating improving fundamentals ahead.
Company is strategically entering a high-growth TAVR market with a $1.5 billion investment, has strong analyst support (92% buy ratings), insider directors purchasing shares, implementing a $2 billion buyback program, and trading at a reasonable valuation of 17x 2026 earnings with projected 16%+ annual earnings growth.
The company announced positive pivotal trial results for its investigational SEISMIQ 4CE catheter, with the device exceeding both primary safety (93.3% vs 86.2% benchmark) and effectiveness endpoints (93.7% vs 85.8% benchmark). This represents a significant advancement in coronary calcium treatment and supports potential FDA approval and market expansion.
The company is strategically expanding its cardiovascular portfolio with an innovative TAVR technology featuring superior design characteristics. The immediate market reaction was positive with a 5.56% stock price increase, and the deal provides access to a less-invasive treatment option in a growing market segment.
Company is accused of making materially false and misleading statements about its U.S. Electrophysiology segment's growth sustainability while concealing adverse facts, resulting in investor losses from missed earnings and weak guidance.
The company is accused of making materially false and misleading statements about its U.S. EP segment's growth sustainability, failing to disclose material adverse trends in procedure volumes, competitive pressures, and regulatory headwinds. Management allegedly lacked reasonable basis for confidence statements and made upward guidance revisions that were materially false.
The company is the subject of a securities class action lawsuit alleging material misstatements and concealment of adverse facts regarding its U.S. Electrophysiology segment's unsustainable growth, resulting in missed earnings and disappointing guidance that caused investor losses.
The company faces a class action lawsuit due to missing earnings guidance, a 17% stock price decline, and allegations of misleading investors about growth projections and competitive market pressures in its key electrophysiology segment.
The company is the subject of a securities class action lawsuit alleging material misstatements and concealment of adverse facts regarding its U.S. Electrophysiology segment's unsustainable growth, resulting in missed earnings and weak guidance that caused investor losses.
The company is the subject of a securities class action lawsuit alleging material misrepresentations and concealment of adverse facts regarding its U.S. Electrophysiology segment's unsustainable growth, resulting in missed earnings and disappointing guidance that caused investor losses.
Company reported lower-than-expected sales, issued weak guidance, experienced a 17.6% stock price decline, and is subject to a securities fraud class action lawsuit alleging potential unlawful business practices.
The company is facing a securities fraud class action lawsuit alleging materially false and misleading statements about its U.S. Electrophysiology business growth. The stock experienced a significant 17.6% decline following disappointing earnings and lowered guidance, indicating investor loss and loss of confidence in management's prior statements.
The company is accused of making materially false and misleading statements about its U.S. Electrophysiology segment's growth sustainability while concealing adverse facts. This resulted in a significant net income miss and disappointing guidance, causing investor losses and triggering a securities class action lawsuit.
The company is the subject of a securities class action lawsuit alleging material misstatements and concealment of adverse facts regarding its U.S. Electrophysiology segment's unsustainable growth, resulting in missed earnings and weak guidance that caused investor losses.
Stock fell 9.32% despite positive clinical trial data (61% reduction in primary endpoint), but Raymond James downgraded from Strong Buy to Outperform and cut price target from $97 to $88
The company is the subject of a securities class action lawsuit alleging management made materially false and misleading statements about the U.S. Electrophysiology segment's sustainability while concealing adverse facts. The undisclosed issues led to a net income miss and underwhelming guidance, causing investor losses.
The company is the subject of a securities class action lawsuit alleging material misrepresentations and concealment of adverse facts regarding its U.S. Electrophysiology segment's unsustainable growth rate, resulting in missed earnings and disappointing guidance that caused investor losses.
Stock declined 9.02% due to underwhelming clinical trial results for its Watchman FLX heart implant. While safety and efficacy endpoints were met, analysts indicated the trial was 'not a home run' with concerns about slower-than-expected growth acceleration.
Despite encouraging trial readouts showing superior safety and efficacy for both WATCHMAN FLX and EKOS systems, the stock declined 9.02% to a 52-week low. The disconnect between positive clinical data and negative price action suggests market concerns about commercialization, valuation, or other factors not reflected in the trial results alone.
The company is the subject of a securities class action lawsuit alleging material misstatements and concealment of adverse facts regarding its U.S. Electrophysiology segment's unsustainable growth, resulting in investor losses when the true details were disclosed.
Company is accused of securities fraud through materially misleading growth projections for its electrophysiology segment. Stock experienced a significant 17.6% decline following corrective disclosure of slower market growth and increased competition. Allegations include knowingly inflating guidance and misrepresenting the sustainability of EP market growth and FARAPULSE's competitive position.
The company is the subject of a securities class action lawsuit alleging material misstatements and concealment of adverse facts regarding its U.S. Electrophysiology segment. Defendants allegedly made positive statements while hiding unsustainable growth rates, resulting in disappointing financial results that harmed investors.
Company faces securities fraud allegations for making false statements about revenue outlook and market share growth. Stock declined 17% after missing earnings guidance ($0.45 EPS vs. guidance of $0.48-$0.52). Allegations include failure to disclose competitive pressures in the electrophysiology market.
The company is the subject of a class action lawsuit alleging material misstatements and non-disclosure of adverse business facts regarding unsustainable growth in its U.S. EP segment, competitive pressures, and misleading guidance to investors. These allegations suggest potential breach of fiduciary duties and investor harm.
Company faces securities fraud allegations for making false statements about revenue outlook and market growth. Stock declined 17% after missing Q4 2025 earnings guidance ($0.45 EPS vs. guidance of $0.48-$0.52), indicating significant investor losses and credibility damage.
Company is accused of disseminating materially false and misleading statements about its U.S. Electrophysiology segment's growth sustainability, resulting in investor losses when true details were revealed.
The company is the subject of a securities class action lawsuit alleging misrepresentations regarding its U.S. electrophysiology segment, which indicates potential fraud and financial misconduct that negatively impacts shareholder value.
Company faces class action lawsuit for allegedly concealing material adverse facts about its U.S. EP segment's unsustainable growth. Stock declined 17.6% following disappointing Q4 2025 earnings and weak 2026 guidance that fell well below market expectations.
Company has strong positioning in age-related medical conditions, consistent double-digit growth, strategic acquisitions (Penumbra, Silk Road Medical), and attractive valuation metrics (forward P/E of 22, PEG ratio of 0.85). Recent stock sell-off due to conservative guidance creates a buying opportunity despite solid fundamentals.
The company experienced a significant 17.6% stock price decline following disappointing fourth quarter 2025 financial results, specifically lower-than-expected sales in its electrophysiology division. Additionally, the company is now subject to a securities fraud investigation and potential class action lawsuit, indicating serious concerns about corporate conduct and investor confidence.
The company faces a significant product safety issue with 167 serious injuries and 3 deaths linked to their AXIOS stent delivery systems, resulting in a mandatory halt and removal of affected devices. This represents a serious regulatory and reputational risk, though the stock was up 2.57% at publication, possibly due to the company's proactive response in addressing the issue.
Articles that tag BSX but are mainly about other companies.
Boston Scientific is included among key companies operating in the Mexico cardiac rhythm management devices market with detailed competitive analysis provided.
Mentioned only as a peer comparison for valuation multiples (trading at similar P/E ratios to Medtronic). No specific sentiment is implied about the company itself.
Posted 9.1% organic Electrophysiology growth with pulsed-field ablation portfolio helping offset competitive pressure, demonstrating competitive positioning in the same market segment as Medtronic.
Experienced a cybersecurity incident in August that disrupted access to systems and business applications, affecting order processing and shipping operations.
Identified as a leading company in the competitive landscape with significant presence in the renal denervation market, benefiting from the projected 19.6% CAGR growth.
Incorporating AI into cardiovascular portfolio with AI-powered imaging platforms and minimally invasive treatments for complex coronary lesions, addressing age-related cardiovascular disease.
Added to Zacks Rank #5 (Strong Sell) list with 1.8% downward revision to current year earnings estimate over the last 60 days
Completed acquisition of Bolt Medical and introduced Seismiq intravascular lithotripsy system in 2025, indicating strategic expansion and strengthened presence in the high-growth IVL technology market.
Mentioned only as the acquirer of Nalu Medical (one of the new board members' previous companies) for $600M in January 2026. This is historical context with no direct impact on Boston Scientific's current operations or strategy.
Boston Scientific is mentioned as a compatible device manufacturer. The mention is neutral as Implicity's algorithm enhances the utility of their devices without directly impacting their core business operations.
Listed among prominent electrosurgery market players expected to benefit from rising surgical volumes and technological innovation in energy-based surgical systems.
Listed among major industry players with strong presence in North America; positioned to benefit from market growth and increasing adoption of robotic endoscopy devices.
Launched innovative WaveOne Dual-mode flexible ureteroscope combining stone visualization and tissue characterization, demonstrating product innovation in the growing urology devices market.
Listed as a leading market player in the disposable endoscopes market, positioned to benefit from the projected 15.04% CAGR growth through 2035.
Listed as a leading market player in the rapidly expanding brain implants market with strong positioning in neuromodulation technologies.
Identified as a leading player in the microcatheter market with premium device specifications and above-market commercial value in North America's interventional cardiology sector.
Stock has fallen over 50% YTD with management repeatedly walking back growth guidance. CEO cited declining Watchman procedure usage and expects flat dollar growth in Q2 and Q3. While analysts remain relatively upbeat, the article warns that achieving the $78 price target consensus may prove challenging without faster-than-expected recovery.
Listed as a major player in the growing peripheral vascular devices market, which is expanding at 5.7% CAGR with strong demand drivers including aging populations and innovations in minimally invasive devices.
Fell 16.95% following multiple analyst price target reductions
Sank 11.7% after management cut full-year organic growth guidance to 6.5%-8% range
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
